Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06952075 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GR1803 Injection in Patients With RRMM

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 2 years or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.
Trial Details
NCT Number NCT06952075
Lead Sponsor Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Multiple Myleoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov